106564670 : Positive, but limited. Pfizer is still on the downward slope of its vaccine business with no clear signs of a turnaround. Pfizer is planning to acquire a weight-loss drug company, entering the competitive market dominated by Eli Lilly and Co and Novo-Nordisk A/S. Short-term results are unlikely, cash flow is declining, and future uncertainties are increasing. If the acquisition succeeds, its rating may be upgraded; otherwise, it will continue to hover at the bottom.